This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

5 Earnings Stocks Poised to Pop

Optimer Pharmaceuticals

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

One earnings short-squeeze candidate in the biotechnology and drugs complex is Optimer Pharmaceuticals (OPTR), which is set to release numbers on Thursday after the market close. This company is focused on discovering, developing and commercializing hospital specialty products. Wall Street analysts, on average, expect Optimer Pharmaceuticals to report revenue of $28.77 million on a loss of 38 cents per share.

If you're looking for one stock that's held up relatively well during the recent market weakness and seen strong upside volume flows, then make sure to take a strong look at shares of Optimer Pharmaceuticals.

The current short interest as a percentage of the float for Optimer Pharmaceuticals is very high at 21.4%. That means that out of the 45.36 million shares in the tradable float, 9.88 million are sold short by the bears. The bears have also been increasing their bets from the last reporting period by 15.3%, or by about 1.3 million shares.

From a technical perspective, OPTR is currently trading above both its 50-day and 200-day moving averages, which is bullish. This stock sold off hard in early April from around $14 to a low of $11.87 a share on monster volume. Following that move lower, shares of OTPR have rebounded sharply towards its current price of $14.77 a share. That move now puts OPTR within range of triggering a major breakout trade post-earnings.

If you're bullish on OPTR, I would look for long-biased trades after its report if this stock manages to break out above some major overhead resistance at $15.12 to $15.40 a share with high-volume. Look for volume on that move that registers near or well above its three-month average action of 645,698 shares. If we get that action, then OPTR should continue its uptrend momentum towards its 2011 high of $17.95 or possibly even $20 a share.

I would simply avoid OPTR or look for short-biased trades if the stock fails to trigger that breakout, and then drops back below its 50-day moving average of $13.57 a share with heavy volume. If we get that action, target a move lower towards its 200-day moving average of $12.48 or possibly even $11 a share if the bears spark a big selloff post-earnings.

5 of 6

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,912.11 -70.48 -0.42%
S&P 500 1,969.95 -8.96 -0.45%
NASDAQ 4,442.6980 -2.2110 -0.05%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs